Article
Endocrinology & Metabolism
Hongyan Liu, Vikas S. Sridhar, Daniel Montemayor, Leif Erik Lovblom, Yuliya Lytvyn, Hongping Ye, Jiwan Kim, Mir Tariq Ali, Daniel Scarr, Patrick R. Lawler, Bruce A. Perkins, Kumar Sharma, David Z. I. Cherney
Summary: The study found that empagliflozin treatment in participants with type 1 diabetes resulted in increased lipid and TCA cycle metabolites, indicating a shift in metabolic substrate use and improved mitochondrial function. These effects lead to more efficient energy production and may contribute to end-organ protection by alleviating local hypoxia and oxidative stress.
DIABETES OBESITY & METABOLISM
(2021)
Article
Cardiac & Cardiovascular Systems
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J. Pocock, Naveed Sattar, Martina Brueckmann, Waheed Jamal, Daniel Cotton, Tomoko Iwata, Faiez Zannad
Summary: The study found that the SGLT2 inhibitor empagliflozin had beneficial effects on patients with heart failure, including reducing the risk of heart failure events, decreasing hospitalizations, and improving health status and functional class. However, the study does not support a dominant role of diuresis in mediating the physiological changes or clinical benefits of SGLT2 inhibitors in patients with reduced ejection fraction.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Tamique Mason, Otavio R. Coelho-Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E. Thorpe, Christopher Bonneau, Hwee Teoh, Richard E. Gilbert, Lawrence A. Leiter, Peter Juni, Bernard Zinman, Michael Jerosch-Herold, C. David Mazer, Andrew T. Yan, Kim A. Connelly
Summary: The study shows that empagliflozin treatment for 6 months can reduce ECV, iECV, and LVMi in individuals with T2DM and CAD, with no impact on MMP-2 and sST2. Further research on the mechanisms of empagliflozin-induced reverse remodeling is needed.
JACC-CARDIOVASCULAR IMAGING
(2021)
Article
Biochemistry & Molecular Biology
Rui Hu, Anita Layton
Summary: The study investigates how kidney function is altered in patients with diabetes and the renal effects of an anti-hyperglyceamic therapy that inhibits SGLT2. Results indicate that SGLT2 inhibition may attenuate glomerular hyperfiltration and reduce single-nephron glomerular filtration rate.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cardiac & Cardiovascular Systems
Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Moellmann, Andras P. Keszei, Michael Boehm, Nikolaus Marx, Michael Lehrke
Summary: Empagliflozin treatment of patients with T2D does not have significant effects on hemodynamic parameters after 1 or 3 days, nor after 3 months, but leads to rapid and sustained significant improvement of diastolic function.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
B. Gaborit, P. Ancel, A. E. Abdullah, F. Maurice, I. Abdesselam, A. Calen, A. Soghomonian, M. Houssays, I. Varlet, M. Eisinger, A. Lasbleiz, F. Peiretti, C. E. Bornet, Y. Lefur, L. Pini, S. Rapacchi, M. Bernard, N. Resseguier, P. Darmon, F. Kober, A. Dutour
Summary: Empagliflozin effectively reduced liver fat in mice and humans without impacting myocardial fat or myocardial energetics, contradicting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Julia Moellmann, Stephanie Wied, Michael Boehm, Hubert Scharnagl, Winfried Maerz, Nikolaus Marx, Michael Lehrke
Summary: Empagliflozin treatment of T2D patients increased levels of LDL-C and LDL apolipoprotein B, but had no effect on calculated LDL particle size.
Article
Health Care Sciences & Services
Sjoukje van der Hoek, Jeroen V. V. Koomen, Erik J. M. van Bommel, Charlotte M. M. Mosterd, Rosalie A. A. Scholtes, Anne C. C. Hesp, Jasper Stevens, Daniel H. H. van Raalte, Hiddo J. L. Heerspink
Summary: This study investigates the effects of two SGLT2 inhibitors on clinical and kidney hemodynamic variables and finds that individual differences in plasma drug exposure may explain inter-individual response variation.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Medicine, General & Internal
Yan Xie, Benjamin Bowe, Andrew K. Gibson, Janet B. McGill, Geetha Maddukuri, Ziyad Al-Aly
Summary: A study using data from the US Department of Veterans Affairs found that among patients with type 2 diabetes receiving metformin therapy, treatment with SGLT2 inhibitors was associated with a reduced risk of all-cause mortality compared to sulfonylureas. This real-world data may help inform the choice of antihyperglycemic therapy for these patients.
JAMA INTERNAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Md Faruque Pathan, Nazma Akter, Shahjada Selim, M. Saifuddin, Nazmul Kabir Qureshi, A. B. M. Kamrul-Hasan, Mohammad Abdul Hannan, Md Ashraf Uddin Ahmed, Marufa Mustari, Ashish Kumar Chakraborty
Summary: Empagliflozin is effective and safe for treating adults with T2DM during Ramadan. It significantly reduces HbA1c and weight without increasing the risk of hypoglycemia and volume depletion.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY
(2022)
Article
Endocrinology & Metabolism
Jack A. Sargeant, James A. King, Thomas Yates, Emma L. Redman, Danielle H. Bodicoat, Sudesna Chatterjee, Charlotte L. Edwardson, Laura J. Gray, Benoit Poulin, Ghazala Waheed, Helen L. Waller, David R. Webb, Scott A. Willis, John P. H. Wilding, Kamlesh Khunti, David J. Stensel, Melanie J. Davies
Summary: This study assessed the impact of the SGLT-2 inhibitor empagliflozin and dietary energy restriction on appetite-regulatory gut peptides in patients with T2D and overweight or obesity. The results showed that empagliflozin therapy did not have a significant effect on appetite-regulatory peptides.
DIABETES OBESITY & METABOLISM
(2022)
Article
Cardiac & Cardiovascular Systems
Milton Packer, Christopher S. S. Wilcox, Jeffrey M. M. Testani
Summary: SGLT2 inhibitors have complex effects on renal tubule function and volume homeostasis, with limited diuretic and natriuretic effects. However, they may result in durable improvement of the internal set point for volume homeostasis. These drugs also exert cardioprotective effects through direct actions on cardiomyocytes. The interplay between changes in volume set point and the direct cellular effects may contribute to the benefits of SGLT2 inhibitors in heart failure.
Review
Pharmacology & Pharmacy
James E. Frampton
Summary: Empagliflozin is a valuable treatment option for ambulant patients with symptomatic chronic heart failure, regardless of their left ventricular ejection fraction. It significantly reduces the risk of cardiovascular death or hospitalization for heart failure and improves health-related quality of life.
Article
Endocrinology & Metabolism
Aline Franco da Rocha, Paulo Sergio Pereira Junior, Gabriela Simonetti Calefi, Guilherme Figueiredo Marquezine, Helena Kaminami Morimoto, Tania Longo Mazzuco, Eliana Cotta de Faria, Mariana Ragassi Urbano, Alexandre Jose Faria Carrilho
Summary: The study investigated the role of growth hormone in promoting ketogenesis in patients treated with empagliflozin. Empagliflozin treatment decreased glucose and free fatty acid concentrations, while increasing beta-hydroxybutyrate levels.
Article
Physiology
Sangita Swapnasrita, Aurelie Carlier, Anita T. Layton
Summary: The kidney plays a vital role in maintaining homeostasis. Diabetes can cause kidney dysfunction, and there may be sex differences in the effects on the kidney. This study used computational models to analyze kidney function in male and female patients with diabetes and evaluated the renal effects of an anti-hyperglycemic therapy.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Endocrinology & Metabolism
Akira Shimada, Toshiaki Hanafusa, Atsutaka Yasui, Ganghyuck Lee, Yusuke Taneda, Akiko Sarashina, Kosuke Shiki, Jyothis George, Nima Soleymanlou, Jan Marquard
DIABETES OBESITY & METABOLISM
(2018)
Article
Endocrinology & Metabolism
Atsutaka Yasui, Ganghyuck Lee, Tetsuaki Hirase, Tatsuroh Kaneko, Stefan Kaspers, Maximilian von Eynatten, Tomoo Okamura
Article
Endocrinology & Metabolism
Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon-Kyu Lee, Ronald Ching Wan Ma, Tien-Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee, Sven Kohler, Yutaka Seino
JOURNAL OF DIABETES INVESTIGATION
(2019)
Article
Endocrinology & Metabolism
Yasuo Terauchi, Kazunori Utsunomiya, Atsutaka Yasui, Tetsuo Seki, Gang Cheng, Kosuke Shiki, Jisoo Lee
Article
Pharmacology & Pharmacy
Kohei Kaku, Masakazu Haneda, Hiroyuki Sakamaki, Atsutaka Yasui, Tatsunori Murata, Anastasia Ustyugova, Rina Chin, Tetsuaki Hirase, Tsunehisa Shibahara, Naoyuki Hayashi, Anuraag Kansal, Stefan Kaspers, Tomoo Okamura
CLINICAL THERAPEUTICS
(2019)
Article
Pharmacology & Pharmacy
Kohei Kaku, Rina Chin, Yusuke Naito, Hristo Iliev, Rie Ikeda, Kaori Ochiai, Atsutaka Yasui
EXPERT OPINION ON DRUG SAFETY
(2020)
Article
Public, Environmental & Occupational Health
Yasuhisa Ono, Yusuke Taneda, Tomomi Takeshima, Kosuke Iwasaki, Atsutaka Yasui
CLINICAL EPIDEMIOLOGY
(2020)
Article
Pharmacology & Pharmacy
Hirotaka Watada, Toshimasa Yamauchi, Fumiko Yamamoto, Atsushi Taniguchi, Larisa Yarush, Clemens Heilmann, Atsutaka Yasui
EXPERT OPINION ON DRUG SAFETY
(2020)
Article
Urology & Nephrology
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze
Summary: SGLT2 inhibitors induce metabolic adaptations similar to aestivation, helping patients adapt to reduced energy availability and conserve water. These metabolic adjustments may contribute to the favorable cardiovascular and renal outcomes of SGLT2 inhibitor therapy.
NATURE REVIEWS NEPHROLOGY
(2021)
Article
Medicine, General & Internal
Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
Summary: This study aims to conduct a randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of the SGLT2 inhibitor empagliflozin on body composition and glycemic control in elderly Japanese patients with T2DM. The trial will assess factors such as muscle mass, muscle strength, and physical performance, as well as patient-reported outcomes, cognitive function, and safety.
Article
Endocrinology & Metabolism
Kohei Kaku, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Atsutaka Yasui, Michaela Mattheus, Soren S. Lund
Summary: This study investigated the effect of empagliflozin on the total burden of cardiovascular and hospitalization events in Asian participants. The results showed that empagliflozin reduced the occurrence of cardiovascular and hospitalization events compared to placebo. This effect was consistent in both Asian and non-Asian populations.
DIABETES OBESITY & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
Summary: This study evaluated the safety and effectiveness of empagliflozin in Japanese patients with T2D. The results showed that empagliflozin is effective and well tolerated in Japanese patients.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Endocrinology & Metabolism
Dae Jung Kim, Wayne H-H Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia-Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Grp
Summary: The EMPA-REG OUTCOME trial showed that empagliflozin, an SGLT2 inhibitor, provides cardiovascular and renal benefits as well as reduces all-cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates the translation of these effects in routine clinical care of type 2 diabetes patients in East Asia.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Article
Endocrinology & Metabolism
Yutaka Seino, Dae Jung Kim, Daisuke Yabe, Elise Chia-Hui Tan, Wook-Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement, Atsutaka Yasui, Wei-Yu Lei, Sunwoo Lee, Moe H. Kyaw, Anouk Deruaz-Luyet, Kimberly G. Brodovicz, Wayne H-H Sheu
Summary: The study evaluated the effectiveness of empagliflozin in reducing risks of heart failure, end-stage renal disease and all-cause mortality compared to DPP-4 inhibitors in East Asian patients with type 2 diabetes. Results showed significant reductions in these risks across countries and regardless of baseline cardiovascular disease status.
ENDOCRINOLOGY DIABETES & METABOLISM
(2021)